Related Experiment Video
Updated: Feb 22, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Glucose-responsive insulin by molecular and physical design
Naveed A Bakh1, Abel B Cortinas1, Michael A Weiss2
1Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Nature Chemistry
|September 23, 2017
Summary
Glucose-responsive insulin (GRI) aims to mimic a natural pancreas by adjusting insulin delivery based on glucose levels. This approach holds promise for a new generation of smart therapeutics.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Medicinal Chemistry
Background:
- The development of advanced diabetes technology seeks to replicate the function of a healthy pancreas.
- Glucose-responsive insulin (GRI) is a therapeutic concept designed to dynamically adjust its action based on a patient's glucose levels.
Purpose of the Study:
- To explore emerging concepts and recent progress in developing glucose-responsive insulin.
- To provide a forward-looking perspective on innovations in insulin molecular engineering and mathematical modeling for GRI.
- To encourage chemists and engineers to contribute to GRI development.
Main Methods:
- Review of recent advancements in molecular engineering of insulin.
- Discussion of mathematical modeling approaches for predicting insulin behavior.
- Analysis of strategies for modulating insulin potency and delivery.
Main Results:
- Emerging concepts in molecular engineering and mathematical modeling are key to achieving viable GRI.
- Recent progress has been made in understanding how to control insulin's response to glucose.
- The development of GRI is a generalized model for future adaptive therapeutics.
Conclusions:
- Glucose-responsive insulin represents a significant step towards a more natural and effective diabetes management.
- Further innovation in synthetic chemistry and chemical engineering is crucial for realizing the full potential of GRI.
- GRI technology offers a promising pathway for a new generation of smart, responsive medications.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
744
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
744
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K
01:28Insulin: The Receptor and Signaling Pathways
3.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.8K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.7K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.7K
01:27Insulin Formulations: Types and Delivery
841
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
841